Download full report with analyst certification and important disclosures
Apr 9 2024, 07:10 IST/BST
hVIVO made significant progress in 2023 with multiple challenge contracts signed and a record number of volunteers inoculated. Top-line growth of 16% drove margin expansion and led to 44% growth in EBITDA. Cash conversion was very strong. The outlook is positive and we are maintaining our forecasts.
Apr 9 2024, 07:10 IST/BST